Search results for " Inhibition"

showing 10 items of 435 documents

Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants

2017

Abstract Background Monoamine oxidases (MAOs) are outer mitochondrial membrane flavoenzymes. They catalyze the oxidative deamination of a variety of neurotransmitters. MAO-A and MAO-B may be considered as targets for inhibitors to treat neurodegenerative diseases and depression and for managing symptoms associated with Parkinson's and Alzheimer's diseases. Purpose The objective was to evaluate the inhibitory effect of Hypericum afrum and Cytisus villosus against MAO-A and B and to isolate the compounds responsible for the MAO-inhibitory activity. Methods The inhibitory effect of extracts and purified constituents of H. afrum and C. villosus were investigated in vitro using recombinant human…

0301 basic medicineMonoamine Oxidase InhibitorsMonoamine oxidaseDrug Evaluation PreclinicalPharmaceutical ScienceGenisteinMixed inhibitionArticleMass SpectrometryInhibitory Concentration 5003 medical and health scienceschemistry.chemical_compoundDrug DiscoveryHumansChrysinMonoamine OxidaseIC50CytisusFlavonoidsPharmacologyPlants MedicinalMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicinechemistryBiochemistryDocking (molecular)AlgeriaMolecular MedicineQuercetinMyricetinQuercetinHypericumPhytomedicine
researchProduct

Auxiliary α2δ1 and α2δ3 Subunits of Calcium Channels Drive Excitatory and Inhibitory Neuronal Network Development

2020

VGCCs are multisubunit complexes that play a crucial role in neuronal signaling. Auxiliary α2δ subunits of VGCCs modulate trafficking and biophysical properties of the pore-forming α1 subunit and trigger excitatory synaptogenesis. Alterations in the expression level of α2δ subunits were implicated in several syndromes and diseases, including chronic neuropathic pain, autism, and epilepsy. However, the contribution of distinct α2δ subunits to excitatory/inhibitory imbalance and aberrant network connectivity characteristic for these pathologic conditions remains unclear. Here, we show that α2δ1 overexpression enhances spontaneous neuronal network activity in developing and mature cultures of …

0301 basic medicineNeurogenesisSynaptogenesisNeurotransmissionInhibitory postsynaptic potentialHippocampusSynaptic Transmission03 medical and health sciencesGlutamatergicMice0302 clinical medicineVGCCsexcitation to inhibition balanceBiological neural networkPremovement neuronal activityAnimalsHumansCalcium SignalingResearch ArticlesNeuronssynaptogenesisChemistryGeneral NeuroscienceGlutamate receptornetwork connectivityRats030104 developmental biologyHEK293 CellsExcitatory postsynaptic potentialalpha2delta subunitsCalcium ChannelsNerve NetNeuroscience030217 neurology & neurosurgeryCellular/MolecularThe Journal of Neuroscience
researchProduct

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

2018

The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneit…

0301 basic medicineOncologyTumor heterogeneitymedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular BiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyInternal medicineImmunology and AllergyMedicineAnimalbusiness.industryMicrobiotaRepertoireMelanomaImmune checkpoints inhibitionAntibodies MonoclonalImmunotherapymedicine.diseaseCancer metabolismGastrointestinal MicrobiomeRadiation therapy030104 developmental biologyCancer stemness signaling030220 oncology & carcinogenesisNeoplasmImmunotherapybusinessHumanCytokine & Growth Factor Reviews
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Pain-Induced Negative Affect Is Mediated via Recruitment of The Nucleus Accumbens Kappa Opioid System.

2019

Negative affective states affect quality of life for patients suffering from pain. These maladaptive emotional states can lead to involuntary opioid overdose and many neuropsychiatric comorbidities. Uncovering the mechanisms responsible for pain-induced negative affect is critical in addressing these comorbid outcomes. The nucleus accumbens (NAc) shell, which integrates the aversive and rewarding valence of stimuli, exhibits plastic adaptations in the presence of pain. In discrete regions of the NAc, activation of the kappa opioid receptor (KOR) decreases the reinforcing properties of rewards and induces aversive behaviors. Using complementary techniques, we report that in vivo recruitment …

0301 basic medicinePainDynorphinNucleus accumbensAffect (psychology)κ-opioid receptorDynorphinsNucleus AccumbensArticle03 medical and health sciencesMice0302 clinical medicineNeuroplasticitymedicineAnimalsValence (psychology)InflammationNeuronsNeuronal Plasticitybusiness.industryMood DisordersGeneral NeuroscienceReceptors Opioid kappaOpioid overdoseNeural Inhibitionmedicine.diseaseRatsAffect030104 developmental biologyOpioidbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugNeuron
researchProduct

Bacterial Biofilm Inhibition in the Development of Effective Anti-Virulence Strategy

2018

There is an urgent need for new therapeutic strategies to counteract the global threat of antibiotic resistance, which has become, in recent years, one of the major public health concern. An important contribution to the microbial survival in hostile environments has been given by the capability of pathogens to form sessile communities able to adhere to biotic or abiotic surfaces, known as biofilms.

0301 basic medicinePharmacologyAntivirulenceChemistry030106 microbiologyBiofilm inhibitionPharmaceutical ScienceVirulenceantibiofilm antivirulenceMicrobiology03 medical and health sciences030104 developmental biologyDrug DiscoveryMolecular MedicineMedicinal ChemistryThe Open Medicinal Chemistry Journal
researchProduct

Substrate Specificity of Aglaia loheri Active Isolate towards P-glycoprotein in Multidrug-Resistant Cancer Cells

2016

Multidrug resistance (MDR) is a major contributory factor in the failure of chemotherapy. Concrete interpretation of P-glycoprotein (P-gp) substrate specificity, whether a substance is a substrate or an inhibitor, represents an important feature of a compound's pharmaceutical profiling in drug design and development. In this work, the P-gp substrate specificity of Maldi 531.2[M+H]+, a phenol ester from Aglaia loheri Blanco leaves was investigated. This study focuses on the effect of Maldi 531.2[M+H]+ on P-gp ATPase activity, which was examined by measuring the amount of inorganic phosphates (Pi) released as a result of ATP hydrolysis. To test the effects of Maldi 531.2[M+H]+ on MDR activit…

0301 basic medicinePharmacologybiologyChemistryStereochemistryStimulationPlant ScienceGeneral MedicineMultiple drug resistance03 medical and health sciences030104 developmental biology0302 clinical medicineNon-competitive inhibitionComplementary and alternative medicineATP hydrolysis030220 oncology & carcinogenesisDrug DiscoveryCancer cellmedicinebiology.proteinPiVerapamilmedicine.drugP-glycoproteinNatural Product Communications
researchProduct

Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake

2017

The extracellular effects of the endocannabinoids anandamide and 2-arachidonoyl glycerol are terminated by enzymatic hydrolysis after crossing cellular membranes by facilitated diffusion. The lack of potent and selective inhibitors for endocannabinoid transport has prevented the molecular characterization of this process, thus hindering its biochemical investigation and pharmacological exploitation. Here, we report the design, chemical synthesis, and biological profiling of natural product-derived N-substituted 2,4-dodecadienamides as a selective endocannabinoid uptake inhibitor. The highly potent (IC50 = 10 nM) inhibitor N-(3,4-dimethoxyphenyl)ethyl amide (WOBE437) exerted pronounced canna…

0301 basic medicinePolyunsaturated Alkamidesmedicine.drug_classmedicine.medical_treatmentAnti-Inflammatory AgentsArachidonic AcidsPharmacologyDepolarization-induced suppression of inhibitionAnxiolyticGlyceridesReuptakeMice03 medical and health scienceschemistry.chemical_compoundCell Line TumorExtracellularmedicineAnimalsHumansReceptors Cannabinoid610 Medicine & healthMice Inbred BALB CMultidisciplinaryHydrolysismusculoskeletal neural and ocular physiologyCell MembraneBrainBiological TransportU937 CellsAnandamideMembrane transportEndocannabinoid systemMice Inbred C57BL030104 developmental biologynervous systemPNAS PlusAnti-Anxiety AgentschemistryBiophysics570 Life sciences; biologylipids (amino acids peptides and proteins)Cannabinoidpsychological phenomena and processesEndocannabinoidsProceedings of the National Academy of Sciences
researchProduct

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

2019

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of i…

0301 basic medicineSettore BIO/17 - IstologiaB7 AntigensT cellIn Vitro TechniquesBiologyLymphocyte ActivationRegenerative medicineCell therapyUmbilical CordImmune toleranceImmunomodulation03 medical and health sciences0302 clinical medicineWharton's jellymedicineHumansWharton JellyCD276Cells CulturedCell ProliferationStem cellMesenchymal stem cellCell DifferentiationMesenchymal Stem CellsHuman umbilical cordCell biologyTransplantationTolerance induction030104 developmental biologymedicine.anatomical_structureB7-H3030220 oncology & carcinogenesisLymphocyte inhibitionRegenerative medicineCytokinesWharton’s jelly mesenchymal stromal cellsStem cell
researchProduct

PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.

2019

Abstract Background and aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor internalization and degradation. PCSK9 has emerged as a novel therapeutic target for hypercholesterolemia. Clinical studies with PCSK9 inhibiting antibodies have demonstrated strong LDL-c lowering effects, but other therapeutic approaches using small molecule inhibitors for targeting PCSK9 functions may offer supplementary therapeutic options. The aim of our study was to evaluate the effect of synthetic EGF-A analogs on mutated (D374Y) PCSK9-D374Y mediated LDLR degradatio…

0301 basic medicineSmall peptidesmedia_common.quotation_subject030204 cardiovascular system & hematologyDecoy strategyPCSK903 medical and health sciences0302 clinical medicineHumansInternalizationCells Culturedmedia_commonExpression vectorEpidermal Growth FactorChemistryPCSK9PCSK9 InhibitorsTransfectionProprotein convertasePCSK9 inhibitionIn vitroCell biologyEGF-A domain030104 developmental biologyLDLRReceptors LDLLDL receptorMutationKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct